Recent patents and patent applications relating to mTOR pathway

Recent Patents on DNA and Gene Sequences

Volumn 3, Issue 1, 2009, Pages 44-52

  Liu, Xiangyu ^a   Yue, Zhenyu ^b  

^a Mount Sinai School of Medicine ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

4EBP1; Akt PKB; Cancer; mTOR; mTORC1; mTORC2; Rapamycin; Rheb; S6K; TSC1 TSC2

Indexed keywords

ACTIN; DEFOROLIMUS; EVEROLIMUS; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SOMATOMEDIN; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE;

ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BIOGENESIS; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; CYTOPLASM; CYTOSKELETON; DIABETES MELLITUS; DNA FLANKING REGION; DOWNSTREAM PROCESSING; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM; ENVIRONMENTAL STRESS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; METABOLIC DISORDER; OBESITY; OXYGENATION; PATENT; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENERAL ASPECTS OF DISEASE; LEGAL ASPECT; METABOLISM; METHODOLOGY; PHYSIOLOGY; SYNTHESIS;

MAMMALIA;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; PATENTS AS TOPIC; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 60549092503     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221509787236192     Document Type: Review

References (76)

1. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253(5022): 905-909.
2. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110(2): 163-175.
3. Liu X, Zheng XF. Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol Biol Cell 2007; 18(3): 1073-1082.
4. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci USA 2000; 97(26): 14340-14345.
5. Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci USA 2002; 99(7): 4319-4324.
6. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124(3): 471-484.
7. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007; 13(6): 252-259.
8. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 1995; 270(5233): 50-1(5233): 50-51.
9. Chen J, Zheng XF, Brown EJ, Schreiber SL. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289- kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci USA 1995; 92(11): 4947-4951.
10. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995; 377(6548): 441-446.
11. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet 1995; 11(2): 115-116.
12. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11(8): 353-361.
13. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12(8): 1007-1018.
14. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307(5712): 1098-1101.
15. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat Cell Biol 2002; 4(9): 648-657.
16. Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 2003; 11(6): 1457-1466.
17. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003; 17(15): 1829-1834.
18. Xu G, Kwon G, Marshall CA, Lin TA, Lawrence JC, McDaniel ML. Branched-chain amino acids are essential in the regulation of PHAS-I and p70 S6 kinase by pancreatic beta-cells. A possible role in protein translation and mitogenic signaling. J Biol Chem 1998; 273(43): 28178-28184.
19. Nobukuni T, Joaquin M, Roccio M, et al. Amino acids mediate mTOR/ raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 2005; 102(40): 14238-14243.
20. Byfield MP, Murray JT, Backer JM. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 2005; 280(38): 33076-33082.
21. Kihara A, Noda T, Ishihara N, Ohsumi Y. Two distinct Vps34 phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y sorting in Saccharomyces cerevisiae. J Cell Biol 2001; 152(3): 519-530.
22. Buerger C, DeVries B, Stambolic V. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun 2006; 344(3): 869-880.
23. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115(5): 577-590.
24. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004; 18(13): 1533-1538.
25. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6(1): 91-99.
26. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003; 13(22): 2004-2008.
27. Yang Q, Guan KL. Expanding mTOR signaling. Cell Res 2007; 17(8): 666-681.
28. Reiling JH, Hafen E, The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev 2004; 18(23): 2879-2892.
29. Li Y, Wang Y, Kim E, et al. Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb. J Biol Chem 2007; 282(49): 35803-35813.
30. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007; 12(3-4): 112-124.
31. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA 2003; 100(25): 15077-15082.
32. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112(12): 1809-1820.
33. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008; 181(2): 293-307.
34. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68(3): 631-634.
35. Kopelovich L, Fay JR, Sigman CC, Crowell, JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007; 16(7): 1330-1340.
36. Contreras CM, Gurumurthy S, Haynie JM, et al. Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res 2008; 68(3): 759-766.
37. Eom M, HanA, Yi SY, Shin JJ, Cui Y, Park KH. RHEB expression in fibroadenomas of the breast. Pathol Int 2008; 58(4): 226-232.
38. Astrinidis A, Henske EP. Tuberous sclerosis complex: Linking growth and energy signaling pathways with human disease. Oncogene 2005; 24(50): 7475-7481.
39. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37(1): 19-24.
40. Bradley RL, Cheatham B. Regulation of ob gene expression and leptin secretion by insulin and dexamethasone in rat adipocytes. Diabetes 1999; 48(2): 272-278.
41. Cota D, Proulx K, Smith KA, et al. Hypothalamic mTOR signaling regulates food intake. Science 2006; 312(5775): 927-930.
42. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431(7005): 200-205.
43. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22(2): 159-168.
44. Sehgal, S.N., Blazekovic, T.M., Vezina, C.: US3929992 (1975).
45. Sehgal, S.N., Blazekovic, T.M., Vezina, C.: US3993749 (1976).
46. Skotnicki, J.S., Leone, C. L., Schiehser, G. A.: US5362718 (1994).
47. Cottens, S., Sedran, R.: US5665772 (1997).
48. Cottens, S., Sedran, R.: US20026440990 (2002).
49. Metcalf, C.A., Rozamus, L.W., Wang, Y., Berstein, D.L.: US20067091213 (2006).
50. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9(5): 341-349.
51. Knight ZA, Gonzalez, B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006; 125(4): 733-747.
52. Hayakawa, M., Kaizawa, H., Moritomo, H., Kawaguchi, K., Koizumi, T., Yamano, M., Matsuda, K., Okada, M., Ohta, M.: WO01083456 (2001).
53. Abraham, R.T.: US20067135298 (2006).
54. Berlin, V., Chiu, M. I., Cottarel, G., Damagnez, V.: US20006150137 ( 2000).
55. Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., Snyder, S. H.: US20026492106 (2002).
56. Clardy, J.C., Choi, J.: US20036532437 (2003).
57. Sabatini, D.M., Kim, D.H., Sarbassov, D.D.: WO04029276 (2004).
58. Sabatini, D.M., Kim, D.H., Sarbassov, D. D.: US20067052870 (2006).
59. Sabatini, D.M., Sarbassov, D. D.: US20060194271 (2006).
60. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/ PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006; 16(18): 1865-1870.
61. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictormTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127(1): 125-137.
62. Finan, P.: WO2008027855 (2008).
63. Guan, K.L.: US20077169594 (2007).
64. Edgar, B.A., Saucedo, L. J.: US20050009112 (2005).
65. Wechsler, R., Mett, I.: US20070281326 (2007).
66. Ha SH, Kim DH, Kim IS, et al. PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 2006; 18(12): 2283-2291.
67. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294(5548): 1942-1945.
68. Ryu, S.H., Suh, P.G., Ha, S.H., Kim, D. H., Kim, I.S., Kim, J.H., Lee, M.N., Lee, H.J., Kim, J.H., Jang, S.K., Lee, T.H.: WO2008016281 (2008).
69. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Cancer Rev 2004; 4(5): 335-348.
70. Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 2004; 279(5): 3327-3339.
71. Sonenberg, N., Gingras, A.-C., Polunavsky, V.A., Bitterman, P.B.: US20030144190 (2003).
72. Sonenberg N, Dever TE. Eukaryotic translation initiation factors and regulators. Curr Opin Struct Bio 2003; 13(1): 56-63.
73. Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med 2001; 7(10): 1128-1132.
74. Monia, B.P., Bhanot, S., Dobie, K. W., Jain, R.: US20050181400 (2005).
75. McDonald PC, Oloumi A, Mills J, et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res 2008; 68(6): 1618-1624.
76. Liotta, L.A., Petericoin, E.F., Espina, V.: WO2007047754 (2007).